Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04684823 · ClinicalTrials.gov registry record · NA

The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis

A NA study of Cystic Fibrosis and Adherence, Medication, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT04684823 is a NA study of Cystic Fibrosis and Adherence, Medication that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 12 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04684823, a NA study of Cystic Fibrosis and Adherence, Medication, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This proposed pilot study will assess if the Patch Technology system will increase adherence in patients with cystic fibrosis followed at the UTHSCSA Cystic Fibrosis Center.

Interventions

  • DEVICE Patch Cap
  • DEVICE Patch App

Study Locations (1)

Texas

  • The University of Texas Health Science Center at San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2021-01-15
Est. Completion 2021-12-27
Phase NA

What the Registry Record Tells You About NCT04684823

The ClinicalTrials.gov registry entry for NCT04684823 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Patch Cap is the first listed.

NCT04684823 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04684823 about?

NCT04684823 is a clinical study titled "The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis". This proposed pilot study will assess if the Patch Technology system will increase adherence in patients with cystic fibrosis followed at the UTHSCSA Cystic Fibrosis Center.

What is the current status of trial NCT04684823?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2021-01-15. Estimated completion is 2021-12-27.

What conditions does trial NCT04684823 study?

This clinical trial studies the following conditions: Cystic Fibrosis, Adherence, Medication.

What interventions are being tested in trial NCT04684823?

The interventions under investigation include: Patch Cap (DEVICE), Patch App (DEVICE).

Who is sponsoring clinical trial NCT04684823?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04684823 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.